Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Rhea-AI Summary

Jyong Biotech (Nasdaq: MENS) announced a non-binding Memorandum of Understanding dated December 4, 2025 with a Vietnam pharmaceutical distributor headquartered in Ho Chi Minh City to evaluate development and commercialization of MCS-2 in Vietnam.

The MOU calls for due diligence and discussions on commercial strategy, regulatory pathway and local execution; it is non-binding and may not result in a definitive agreement. The company said MCS-2 remains an investigational new drug candidate not approved in any jurisdiction. The MOU follows a November 24, 2025 non-binding Letter of Intent with a South Korean pharmaceutical company to explore in-licensing and development of plant-derived MCS products.

News Market Reaction – MENS

-0.21%

6 alerts

-0.21% News Effect

-6.3% Trough in 25 hr 51 min

-$4M Valuation Impact

$2.13B Market Cap

0.2x Rel. Volume

On the day this news was published, MENS declined 0.21%, reflecting a mild negative market reaction. Argus tracked a trough of -6.3% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $4M from the company's valuation, bringing the market cap to $2.13B at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $2.35 Vol: Volume 70,652 is 0.36x th...

low vol

$2.35 Last Close

Volume Volume 70,652 is 0.36x the 20-day average of 199,018, indicating subdued trading. low

Technical Shares at $26.64 are trading below the 200-day MA of $36.71 and 60.24% under the 52-week high.

Peers on Argus

While MENS fell 7.37%, key biotech peers like CRSP (+2.18%), PTCT (+1.63%), and ...

While MENS fell 7.37%, key biotech peers like CRSP (+2.18%), PTCT (+1.63%), and TGTX (+4%) were positive, pointing to a company-specific move rather than sector pressure.

Historical Context

5 past events · Latest: Dec 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 04	Regional MOU	Neutral	-2.1%	Non-binding MOU to explore MCS-2 commercialization in Vietnam.
Nov 24	Partnership LOI	Positive	+15.2%	Non-binding LOI with South Korean pharma to in-license MCS-2.
Nov 20	Clinical results	Positive	+12.4%	Positive Phase II outcomes for MCS-8 with reduced prostate cancer incidence.
Sep 29	Award & NDA	Positive	-16.3%	Innovation award for BOTRESO and U.S. FDA NDA submission.
Sep 18	Conference appearance	Neutral	-3.6%	CEO scheduled as speaker at Global Business Forum in Taipei.

Pattern Detected

The stock has shown mixed reactions to news: strong gains on positive clinical and partnership updates, but sharp selloffs even on seemingly favorable recognition and awards.

Recent Company History

Over the last few months, Jyong Biotech has reported several milestones, including a positive Phase II readout for MCS-8 with double-digit percentage stock gains, and a non-binding LOI in South Korea that also lifted shares. However, an innovation award and NDA submission were followed by a 16.3% decline, highlighting volatile sentiment. Today’s Vietnam MCS-2 MOU continues the company’s regional partnering strategy but coincides with a pre-news price 7.37% pullback and light volume.

Market Pulse Summary

This announcement adds another step in Jyong Biotech’s Asia-focused partnering strategy by exploring...

Analysis

This announcement adds another step in Jyong Biotech’s Asia-focused partnering strategy by exploring MCS-2 commercialization in Vietnam under a non-binding MOU. It follows a recent South Korean LOI and comes while MCS-2 remains an investigational candidate without approvals. Investors may track whether due diligence yields a definitive agreement, how the regulatory pathway in Vietnam is defined, and how this complements prior clinical progress for related plant-derived programs such as MCS-8.

Key Terms

memorandum of understanding, due diligence, regulatory pathway, investigational new drug

4 terms

memorandum of understanding financial

"announced that it has entered into a non-binding Memorandum of Understanding"

A memorandum of understanding (MOU) is a formal agreement between two or more parties that outlines their shared intentions and plans to work together. It acts like a handshake in writing, clarifying each side’s roles and expectations before any official contract is signed. For investors, an MOU signals that parties are serious about collaboration, which can influence future business opportunities and potential growth.

due diligence financial

"will proceed with due diligence and discussions to determine the scope"

Due diligence is the careful investigation and analysis someone conducts before making a decision, such as investing money or entering into an agreement. It’s like researching thoroughly before buying a used car to ensure it’s in good condition; this helps prevent surprises and makes informed choices. For investors, due diligence reduces risk by verifying details and understanding what they’re getting into.

regulatory pathway regulatory

"including commercial strategy, regulatory pathway and local market execution"

A regulatory pathway is the official process a product or service must follow to gain approval from government authorities before being offered to the public. It outlines the steps, tests, and reviews needed to demonstrate safety, effectiveness, or compliance. For investors, understanding the regulatory pathway helps assess how quickly and easily a product can reach the market and generate revenue.

investigational new drug regulatory

"MCS-2 remains an investigational new drug candidate and has not been approved"

An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

AI-generated analysis. Not financial advice.

New Taipei City, Taiwan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company” or “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced that it has entered into a non-binding Memorandum of Understanding (the “MOU”) with a Vietnam‑based pharmaceutical distribution company headquartered in Ho Chi Minh City, to evaluate the development and commercialization of MCS‑2 in the Vietnam pharmaceutical market.

Under the terms of the MOU, Jyong Biotech and the Vietnam pharmaceutical distribution company will proceed with due diligence and discussions to determine the scope and structure of any definitive collaboration, including commercial strategy, regulatory pathway and local market execution. There can be no assurance that any definitive agreement will be reached or that any contemplated collaboration will be consummated.

Fu Feng Kuo, CEO and Chairwoman of Jyong Biotech, commented, “This MOU represents an important step in our Asia‑focused strategy to bring plant‑derived MCS therapies to new markets. Vietnam presents meaningful opportunities for patient access and local partnership, and we are committed to working closely with our prospective partner to evaluate viable regulatory and commercial pathways while safeguarding the scientific and clinical integrity of MCS‑2.”

The MOU follows Jyong Biotech’s previously announced non‑binding Letter of Intent with a South Korean pharmaceutical company to evaluate in‑licensing and development opportunities for plant‑derived MCS products, announced on November 24, 2025.

As of present day, MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction. Jyong Biotech will comply with applicable regulatory disclosure obligations and provide timely, accurate, and complete updates on material developments.

About Jyong Biotech Ltd.

Headquartered in Taiwan, Jyong Biotech Ltd. is a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, BOTRESO®, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers’ health needs and seeks to be a valuable business organization that is held in high esteem by the public.

For more information, please visit: https://www.jyongbio.com/, https://jyongir.com/.

Forward-Looking Statement

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

Jyong Biotech Ltd.
ir@jyongbio.com

Investor Relations
WFS Investor Relations Inc.
Email: services@wealthfsllc.com
Phone: +1 628 283 9214

FAQ

What did Jyong Biotech (MENS) announce on December 4, 2025 about MCS-2 in Vietnam?

Jyong Biotech announced a non-binding MOU with a Vietnam pharmaceutical distributor to evaluate development and commercialization of MCS-2 in the Vietnam market.

Does the December 4, 2025 MOU between Jyong Biotech (MENS) and the Vietnam distributor create a binding deal?

No; the arrangement is a non-binding MOU that requires due diligence and further negotiations before any definitive agreement.

Is MCS-2 approved for commercial use following the MOU announced by Jyong Biotech (MENS)?

No; MCS-2 remains an investigational new drug candidate and has not been approved for commercial use in any jurisdiction.

How does the Vietnam MOU relate to Jyong Biotech's Asia strategy for MCS products (MENS)?

The company said the MOU is part of an Asia-focused strategy to evaluate regulatory and commercial pathways and expand patient access for plant-derived MCS therapies.

What are the next steps after the MOU for Jyong Biotech (MENS) and the Vietnam partner?

The parties will conduct due diligence and discuss scope, commercial strategy, regulatory pathway, and local market execution to determine any definitive collaboration.